A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates

Leonard Howell, Emory University
Jonathon A Nye, Emory University
Jeffrey Scott Stehouwer, Emory University
Ronald Voll, Emory University
Jiyoung Mun, Emory University
D. Narasimhan, Emory University
J. Nichols, Emory University
R. Sunahara, Emory University
F.I. Carroll, Emory University
J.H. Woods, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Translational Psychiatry
Volume: Volume 4, Number 7
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/tp.2014.48
Permanent URL: http://pid.emory.edu/ark:/25593/gk4wn

Final published version: http://www.nature.com/tp/journal/v4/n7/full/tp201448a.html

Copyright information:
© 2014 Macmillan Publishers Limited
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits distribution, public display, and publicly performance, making multiple copies, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact. This license prohibits exercising rights for commercial purposes.

Accessed January 27, 2018 11:57 PM EST
A long-acting, thermostable bacterial cocaine esterase (CocE) has been identified that rapidly degrades cocaine with a $K_m$ of 1.33 ±0.085 μM. In vivo evaluation of CocE has shown protection against convulsant and lethal effects of cocaine in rodents, confirming the therapeutic potential of CocE against cocaine overdose. However, the current study is the first to evaluate the effects of CocE on cocaine brain levels. Positron emission tomography neuroimaging of $[^{11}C]$cocaine was used to evaluate the time course of cocaine elimination from brain in the presence and absence of CocE in nonhuman primates. Systemic administration of CocE eliminated cocaine from the rhesus-monkey brain approximately three times faster than control conditions via peripheral actions through attenuating the input function from blood plasma. The efficiency of this process is sufficient to alleviate or prevent adverse central nervous system effects induced by cocaine. Although the present study used tracer doses of cocaine to access brain clearance, these findings further support the development of CocE for the treatment of acute cocaine toxicity.

**ORIGINAL ARTICLE**

A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates

LL Howell, JA Nye, JS Stehouwer, RJ Voll, J Mun, D Narasimhan, J Nichols, R Sunahara, MM Goodman, FI Carroll and JH Woods

**INTRODUCTION**

Searching for sensitive methods to detect illicit cocaine, a group in Cambridge, England investigated the presence of cocaine biosensors in a Rhodococcus bacterium that inhabits the soil of the coca plant rhizosphere. They isolated, identified, sequenced and cloned a gene that encodes cocaine esterase (CocE), by this bacterium and degrades cocaine into inactive metabolites, ecgonine methyl ester and benzoic acid, with a $K_m$ of 1.33 ±0.085 μM. The possibility that such an enzyme could be useful in the treatment of cocaine overdose was noted by a group at the Scripps Research Institute in 2002. This group crystallized and further characterized the enzyme, determining the kinetics of CocE as: $k_{cat} = 7.8 \, s^{-1}$ and $K_m = 640 \, nM$. In vivo evaluation of CocE's actions against cocaine demonstrated the ability of the enzyme to protect against the convulsant and lethal effects of cocaine in rodents. Hence, the therapeutic potential of CocE against cocaine overdose has been confirmed.

The native CocE protein has a short enzymatic half-life in plasma at normal physiological temperature (37 °C). However, two amino acid changes based off in silico analysis were able to increase its half-life from 15 min to over 4 h without altering the enzyme's hydrolytic activity. The stabilized form of the enzyme eliminates the cardiovascular effects of systemically delivered cocaine. Even if cocaine had initiated a seizure as indicated by EEG recordings, it could be quickly terminated by intravenous delivery of the enzyme. These data raised the interesting question regarding the site of CocE's action. Due to its large size, the enzyme is unlikely to enter the brain following systemic administration. Accordingly, its effects are likely to be exclusively due to its capacity to act as a peripheral 'sink' to draw cocaine out of the brain and hydrolyze it in the periphery.

To confirm this theoretical framework, we prepared the double mutant CocE in a bacterial cell line that expressed no endotoxin, radiolabeled cocaine with $[^{11}C]$ and used positron emission tomography (PET) neuroimaging to evaluate the time course of cocaine elimination from brain in the presence and absence of CocE in rhesus monkeys. We hypothesized that the presence of CocE in plasma would accelerate the elimination of cocaine from brain. As a negative control, we evaluated the cocaine analog RTI-150 which lacks the benzoyl ester linkage of cocaine but has characteristic cocaine-like effects on behavior and dopamine neurochemistry in nonhuman primates. If our suppositions were correct, CocE should have no effect on the pharmacokinetic profile of RTI-150.

**MATERIALS AND METHODS**

**Subjects**

Three adult rhesus monkeys (RGg-9, RZq-8 and RLa-10) weighing between 8.1–9.8 kg served as subjects. Each subject was housed individually and fed Purina monkey chow (Ralston Purina, St Louis, MO, USA), fruits and vegetables. Water was continuously available. Animal care procedures strictly followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of Emory University. All subjects received $[^{11}C]$ cocaine and two subjects (RGg-9 and RZq-8) also received $[^{11}C]$RTI-150.

**Radioligands**

Cocaine was obtained from the National Institute on Drug Abuse, Bethesda, MD, USA, and RTI-150 was obtained from Research Triangle Institute, Research Triangle Park, NC, USA. $[^{11}C]$Cocaine and $[^{11}C]$RTI-150 were synthesized using methods previously established by our laboratory. The chemical structures and labeling for each drug are shown in Figure 1.

**CocE production**

Plasmid expressing double mutant CocE (DM CocE) is described previously. Plasmid pET22bDMCocE was used to transform FreColi cells (RCT Technologies, Tucson, AZ, USA). Transformed cells were grown in TB media containing ampicillin antibiotic. Cells were induced with 1 mM IPTG
Saline solution or saline alone as a control. Images were reconstructed with OSEM/ MAP using measured attenuation correction, zoom factor 2, and decay corrected to the time of injection.

Data analysis

Regions of interest (ROIs) were drawn manually on each animal’s PET images fused with a rhesus MRI template over the caudate and putamen. An additional reference region was drawn over the cerebellum, which was assumed to have a negligible concentration of the dopamine transporter (DAT). The same regions were used for the saline and CocE challenges within the same animal. Regions of interest were then applied to all images to obtain time-activity curves and then normalized to the animal’s body weight and injected activity.

The pharmacokinetics of [11C]cocaine uptake into the brain were simulated using mathematical compartmental analysis commonly applied in the quantification of blood flow, cerebral metabolism and neuroreceptor binding. Compartmental representing physiological spaces or states of [11C]cocaine in the DAT-rich regions and in the esterase challenge are assigned to the (1) blood plasma, a space representing the amount of [11C]cocaine available to cross the blood brain barrier, (2) interstitial region, a space representing the free and nonspecific bound fraction of [11C]cocaine and (3) bound state, representing [11C]cocaine that is specifically bound to the DAT. The plasma input concentration of [11C]cocaine is not explicitly known in these experiments, therefore it is estimated from the cerebellum which is assumed to have negligible specifically bound signal. The cerebellum can be modeled using only two compartments, (1) blood plasma, this is the same compartment as above and (2) reference region, representing the same compartment as interstitial region but in the cerebellum region. The use of a reference region for estimating the plasma input has been shown to be valid in the calculation of specifically bound signal in neuroreceptor studies. The addition of the interstitial region and bound state compartments represents the observed PET signal in the imaging studies.

Kinetic analysis of the time-activity was performed with the General Reference Tissue Model, a modification of the Lammertsma model allowing for the initial compartment concentrations to be nonzero. The model rate constants describe a first-order exchange between compartments using the reference region as the plasma input function. The rate constants used in the model are: R—the ratio of plasma to extracellular rate constant of the striatum and reference region (K_i/K_o), k_2—the extracellular to plasma rate constant in the striatum (where, k_2 = k_f/K in the reference region), k_3—konBavail the DAT association rate (kon) times the number of available binding sites (Bavail) and k_4—the disassociation rate from the DAT.

The model is solved by initially assigning values to the rate constants (R, k_2, k_3, k_4), comparing the model generated time-activity curve with the PET time-activity curve, calculating the least squares sum, then iteratively adjusting the rate constants such that the least squares sum is minimized. The minimization of the least squares is done in a computer environment (IDL 6.4, ITI Visual Information Solutions, Boulder, CO, USA). An estimate of available DAT was then calculated from the calculated rate constants calculated from the binding potential, BP_{ND} = kon × Bavail/koff = k_3/k_4. BP_{ND} is assumed to be constant throughout the experiment; therefore BP_{ND} represents the number of available DAT sites for binding with [11C]cocaine.

In addition to the compartment model, the washout rate of [11C]cocaine from the striatum was calculated using time-activity data following the peak uptake and fitting that data with an exponential function and a constant (e/(t-τ)+C), where τ (1 min⁻¹) is the washout rate and C is a constant. A Mann-Whitney U test (nonparametric t-test) was used to compare statistically the washout rate between saline and CocE challenges.

Simulation data

It was hypothesized that there is a marked reduction in [11C]cocaine available in the plasma compartment to enter the brain interstitial space immediately following the esterase challenge. The pharmacokinetics of the rapid metabolism of [11C]cocaine were simulated by setting K_i, the rate constant describing the influx of [11C]cocaine to the brain, to zero at 10 min post radiopharmaceutical injection and at the time of esterase injection. The influx rate constants can be estimated directly from a two-tissue compartment model if the arterial input function is known. In the present case, the input function is the cerebellum, which is assumed to have a negligible concentration of DAT and therefore represents signal from the free interstitial space and blood.
Mean time-activity curves were created for the [11C]cocaine CocE or saline control challenges by averaging the caudate and cerebellum time-activity curves from all three subjects. These averaged time-activity curves were fit with the General Reference Tissue Model to estimate the rate constants ($R$, $k_2$, $k_3$, $k_4$). At 10 min, the DAT-rich compartment model was used to simulate the esterase challenge by assigning the compartment concentrations and rate constant calculated from the General Reference Tissue Model. In the DAT-rich compartment model, $K_1$ was set to zero at 10 min, and was run from 10 min to 120 min to obtain the specifically bound compartment concentration over time. This simulation assumes that the introduction of the esterase compound does not alter the rate constants governing the binding of [11C]cocaine to DAT ($k_3$) or its elimination from brain ($k_2$ and $k_4$).

RESULTS

PET images for a representative subject (RGg-9) are shown in Figure 2. Note the high uptake of [11C]cocaine in the caudate and putamen, two regions of interest with high DAT density. [11C]cocaine binding diminished over 50 min following saline challenge. The reduction in [11C]cocaine binding over time was markedly accelerated following CocE challenge, indicating rapid elimination of cocaine from brain.

Subsequent analyses quantified the pharmacokinetics of [11C]cocaine binding. The regions of interest (caudate and putamen) and the reference region (cerebellum) were used to evaluate the time course for [11C]cocaine uptake and elimination. Time-activity curves are shown for individual subjects in Figure 3, and rate
constants and BPND are reported in Table 1. The average time to peak levels of cocaine was 9.5 min, and cocaine levels dropped markedly after 40–50 min. CocE induced a significant increase in the elimination rate for cocaine ($P < 0.05$). The elimination rate for cocaine in caudate/putamen was 3.0 ± 0.7% per minute following saline and 8.0 ± 1.0% per minute following CocE. Hence, CocE induced approximately a three-fold increase in cocaine elimination from brain. There was no significant difference in BPND between the saline and esterase challenges in the caudate ($P = 0.47$) or putamen ($P = 0.51$), indicating that CocE-induced changes in the time-activity curves and brain elimination were exclusively due to reduced cocaine concentrations in blood. In contrast, the time to peak levels of $[^{11}C]$RTI-150 was considerably greater, and drug levels were sustained for the duration of the 90-min session (Figure 4 and Table 2). As predicted, CocE had no effect on the elimination rate of the cocaine analog RTI-150, which lacks the benzoyl ester linkage of cocaine.

Figure 5 shows the averaged time-activity curves and simulated model to demonstrate the consequence of $K_1$ going to zero immediately after esterase challenge, indicating the absence of $[^{11}C]$cocaine in blood for transport to the brain. Note the elimination of cocaine in the simulation was slightly faster than the measured data suggesting that $[^{11}C]$cocaine was not completely eliminated from the blood at the time of CocE injection but substantially reduced compared with saline.

### DISCUSSION

Cocaine overdose can result in profound cardiovascular and central nervous system alterations that are frequently lethal. Nevertheless, standard care for cocaine overdose primarily
involves symptomatic treatment that is often insufficient. The usefulness of pharmacokinetic approaches to cocaine overdose has been recently suggested and our previous data on the pharmacokinetics of CocE in rhesus monkeys support this suggestion. This earlier work in monkeys on the kinetics of plasma cocaine elimination in the absence and presence of CocE indicated that, when administered alone, cocaine had a half-life of 50.7 min. Administration of 0.32 mg kg−1 CocE before cocaine resulted in plasma levels of cocaine that were below detection at the first measurement time of 5−7 min.

The research presented here using PET neuroimaging technology demonstrated that peripheral administration of CocE removed cocaine from the rhesus-monkey brain approximately three times faster than the non-CocE control condition. CocE did not alter elimination of non-esteratic RTI-150, indicating that CocE was hydrolyzing cocaine at its ester bond, which is located between ecgonine methyl and the benzoyl moiety. Despite the rapid removal of cocaine from the circulating periphery, PET neuroimaging indicated that there were measurable levels of cocaine in the brain 20 min following CocE administration. The fact that no cocaine was detected in plasma at this time indicates that CocE’s site of action is exclusively in the periphery. Ostensibly, cocaine is removed from the brain down its concentration gradient through circulation to the periphery where it is quickly metabolized by CocE; cocaine-free blood is returned to the brain. CocE-induced changes in the rate of [11C]cocaine crossing the blood brain barrier were simulated in the current study indicates that protection will also be afforded to central nervous system effects at an only slightly slower rate. The results further support the development of CocE for the treatment of acute cocaine toxicity.

CoC for the treatment of acute cocaine toxicity
LL Howell et al

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
We thank both Juliet Brown and Lisa Neidert for their expert technical assistance. These studies were supported by USPHS grants DA010344, DA031246 and the Office of Research Infrastructure Programs OPPD1OD11132.

REFERENCES
